- Company
- Baxter-Boryung shake hands on comarketing PN in Korea
- by Eo, Yun-Ho Feb 12, 2020 06:28am
- Boryung Pharmaceutical is to reinforce the sales capacity in Korea for Baxter’s nutrition solution pipeline. Baxter (GM Hyun Dong-wook) announced on Feb. 10 of signing a business partnership agreement with Boryung Pharmaceutical (Co-CEO Ahn Jae-hyun, Lee Sam-soo) on co-marketing the company’s Olimer and two other major nutrition soluti
- Company
- Lipitor won the market in the 2010s
- by An, Kyung-Jin Feb 12, 2020 06:27am
- In the past decade, Lipitor, the hyperlipidemia drug, recorded the most outpatient prescriptions. Lipitor has been prescribed a total of &8361;1.31 trillion since 2010. After the patent expiration in 2009, even in the offensive of generic drugs, Lipitor showed that it never fell below the second place in prescriptions. The hepatitis B d
- Company
- JAK-inhibiting oral antirheumatic drug market getting fuller
- by Eo, Yun-Ho Feb 11, 2020 06:31am
- Orally taken antirheumatic treatment, JAK inhibitor drug market in Korea would be soon led by four competitors. According to pharmaceutical industry, the close competition between Pfizer’s Xeljanz (tofacitinib) and Lilly’s Olumiant (baricitinib) would get even intensified as Astellas Pharma’s Smyraf (peficitinib) entered the competit
- Company
- Pfizer recalling Lipitor and Caduet in defective packaging
- by Jung, Hye-Jin Feb 11, 2020 06:29am
- Pfizer Korea is recalling some of Lipitor and Caduet stocks, not because of the drug itself but because of defective packaging. On Feb. 6, Pfizer Korea disseminated official notice to vendors and requested them to suspend shipping of Lipitor and Caduet. The shipping is halted for Lipitor 10 mg in 90-tablet packaging with manufacturer
- Company
- MSD’s Spin off completes within this year
- by An, Kyung-Jin Feb 10, 2020 06:31am
- Employees of Korean subsidiaries had begun to stir as Merck (US MSD) declares a division of business. Anxiety over future behaviors is heightening as the company announces the launch of an independent corporation to manage women's health-related products, patent expired drugs, and biosimilars within the year. Decision to split MSD busines
- Company
- AstraZeneca, decided to withdrawal from the KDPU
- by Kim, Jin-Gu Feb 10, 2020 06:31am
- AstraZeneca Korea decided to withdraw from the KDPU(Korea Democratic Pharmaceutical Union). The branches of the KDPU have been reduced to 18, including 17 multinationals and 1 domestic. According to the pharmaceutical industry on the 6th, the Branch of AstraZeneca Korea under the KDPU has voted for members whether or not to withdraw from t
- Company
- Ilyang's Supect, good effect on leukemia cells reduction
- by Jung, Hye-Jin Feb 10, 2020 06:30am
- Ilyang announced that its phase III clinical trial of 'Supect', a leukemia treatment drug developed by the company, outperformed than Glivec. Ilyang Pharmaceutical (President Kim Dong-yeon) announced on the 6th that the clinical results were published in British journal of Hematology. In this trial, 241 patients with chronic myelogenous
- Company
- MFDS to clear Forxiga’s heart failure indication soon
- by Eo, Yun-Ho Feb 10, 2020 12:17am
- Anti-diabetic treatment Forxiga is ready to be reintroduced as a heart failure drug in Korean market as well. According to pharmaceutical industry on Feb. 7, AstraZeneca’s sodium-glucose cotransporter 2 (SGLT-2) inhibitor Forxiga (dapagliflozin) would be soon indicated for reducing the risk of hospitalization by heart failure in patients
- Company
- Opdivo retries expanding reimbursement without NSCLC
- by Eo, Yun-Ho Feb 6, 2020 06:31am
- Seemingly have given up on expanding reimbursement, Opdivo has turned around and started taking actions again. Nevertheless, its health coverage application excluded indication for lung cancer. According to industry sources, Ono Pharmaceutical and BMS have recently applied for expanding reimbursement on PD-1 inhibitor-based immunotherapy
- Company
- Pelubi’s indication expansion, seeking for breakthrough
- by Kim, Jin-Gu Feb 6, 2020 06:30am
- Daewon Pharm challenges the expansion of Pelubi's patented indication. Pelubi's indication for osteoarthritis is extended to dysmenorrhea. Recently, Pelubi CR’s phase III trial plan by Daewon was approved from the Ministry of Food and Drug Safety. This is a phase III clinical trial in Korea to evaluate the efficacy and safety of DW9801
